Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Yamaguchi (Nagakute, Japan), K. Kosaka (Nagakute, Japan), T. Yonezawa (Nagakute, Japan), H. Shibata (Nagakute, Japan), A. Matsubara (Nagakute, Japan), T. Kato (Nagakute, Japan), H. Tanaka (Nagakute, Japan), N. Yokoe (Nagakute, Japan), S. Ito (Nagakute, Japan), A. Kubo (Nagakute, Japan). Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis. 3017

Member's Comments

No comment yet.

Related content which might interest you: Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 The effect of pentoxifylline on IL-12 and IL-18 release by alveolar macrophages in sarcoidosis and hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Lymphocytes populations in bloods and lungs in patients with auto-immune pulmonary alveolar proteinosis Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011 Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Production of IL-12 and IL-18 by alveolar macrophages in acute and chronic hypersensitivity pneumonitis Source: Eur Respir J 2005; 26: Suppl. 49, 469s Year: 2005 Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Cross-sectional and longitudinal measurement of autoantibody levels against GM-CSF is useful for predicting clinical courses of in autoimmune pulmonary alveolar proteinosis. Source: International Congress 2017 – Rare diseases Year: 2017 The role of apoptosis in idiopathic pulmonary alveolar proteinosis Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Plasmapheresis for treatment of pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1220-1222 Year: 2009 Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphysema Source: Eur Respir J 2009; 33: 219-221 Year: 2009 Increased production of caspase-1 by alveolar macrophages in patients with pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002 Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016